Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials.
- Citation:
- J Clin Oncol vol 28 (15 (May 20 Supplement)) 7637
- Meeting Instance:
- ASCO 2010
- Year:
- 2010
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- Yes
- Parents:
- None
- Children:
- 278
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- N. R. Foster Y. Qi Q. Shi J. E. Krook J. W. Kugler J. R. Jett J. R. Molina S. E. Schild A. A. Adjei S. J. Mandrekar
- Networks:
- Study
- NCCTG-N0424
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- Keywords: